Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 vs placebo with mFOLFOX6 in chemorefractory metastatic colorectal cancer
2010-023050-37Phase 2Active
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) and colorectal adenocarcinoma comparing BIBF 1120 + mFOLFOX6 with Placebo + mFOLFOX6 (2 arms). Primary endpoint: Progression-free survival. Started Mar 2011; status: active.
02
Drugs
nintedanib
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2010-023050-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023050-37.